S-4321, a dual-cell bidirectional antibody that agonizes inhibitory receptors at the T cell-APC synapse
Dec. 4, 2024
Seismic Therapeutic Inc. has provided preclinical data for S-4321, a novel dual-cell bidirectional (DcB) PD-1:FcγRIIb antibody being developed for the treatment of autoimmune disease.
